Guanfacine ER — $0 on Listed Strengths
Guanfacine ER is $0 on listed strengths only. Other strengths are not a blanket $0.
Guanfacine ER Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | $0 on listed strengths |
| Typical Retail | $97.00 |
$0 on listed strengths: 1mg Tablets (max 90); 2mg Tablets (max 90); 3mg Tablets (max 90); 4mg Tablets (max 90)
About Guanfacine ER
Guanfacine ER is a prescription medication. Ask your doctor if Guanfacine ER is right for you.
Other strengths and forms of Guanfacine
How to Check Guanfacine ER Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Guanfacine ER at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
About Guanfacine ER
Guanfacine ER is a medication often prescribed to help manage conditions like ADHD and high blood pressure. Understanding how it works and its typical costs is crucial for your health journey. The good news? With TheDrugClub, accessing your Guanfacine ER just got significantly easier and more affordable, potentially costing you $0 out-of-pocket.
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.
What Guanfacine ER is approved for (FDA label)
Guanfacine extended-release tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications [see CLINICAL STUDIES (14)].
Source: Read the full FDA label on DailyMed. Label effective date: January 22, 2025.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Guanfacine ER (FDA label)
Guanfacine extended-release tablets, USP 1 mg are white to off-white, round, biconvex tablets, engraved "APO" on one side, "GU1" on the other side. Guanfacine extended-release tablets, USP 2 mg are white to off-white, oval shaped, biconvex tablets, engraved "APO" on one side, "GUA 2" on the other side. Guanfacine extended-release tablets, USP 3 mg are green, round, biconvex tablets, engraved "APO" on one side, "GU3" on the other side. Guanfacine extended-release tablets, USP 4 mg are green, oval shaped, biconvex tablets, engraved "APO" on one side, "GUA 4" on the other side.
Source: FDA prescribing information (DailyMed). Set ID: fae2df3c-2298-a3e1-e053-6294a90aeac4. SPL document ID: 2c4def88-252f-7c8b-e063-6294a90aeb94. Label effective date: January 22, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Guanfacine ER (FDA label)
The following serious adverse reactions are described elsewhere in the labeling: Hypotension, bradycardia, and syncope [see WARNINGS AND PRECAUTIONS (5.1)] Sedation and somnolence [see WARNINGS AND PRECAUTIONS (5.2)] Cardiac conduction abnormalities [see WARNINGS AND PRECAUTIONS (5.3)] Rebound Hypertension [see Warnings and Precautions (5.4)] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described below reflect clinical trial exposure to guanfacine extended-release tablets in 2,825 patients.
Source: FDA prescribing information (DailyMed). Set ID: fae2df3c-2298-a3e1-e053-6294a90aeac4. SPL document ID: 2c4def88-252f-7c8b-e063-6294a90aeb94. Label effective date: January 22, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Guanfacine ER (FDA label)
Guanfacine extended-release tablets are contraindicated in patients with a history of a hypersensitivity reaction to guanfacine extended-release tablets or its inactive ingredients, or other products containing guanfacine. Rash and pruritus have been reported.
Source: FDA prescribing information (DailyMed). Set ID: fae2df3c-2298-a3e1-e053-6294a90aeac4. SPL document ID: 2c4def88-252f-7c8b-e063-6294a90aeb94. Label effective date: January 22, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Guanfacine ER (FDA label)
5.1 Hypotension, Bradycardia, and Syncope Treatment with guanfacine extended-release tablets can cause dose-dependent decreases in blood pressure and heart rate. Decreases were less pronounced over time of treatment. Orthostatic hypotension and syncope have been reported [see ADVERSE REACTIONS (6.1)]. Measure heart rate and blood pressure prior to initiation of therapy, following dose increases, and periodically while on therapy. Titrate guanfacine extended-release tablets slowly in patients with a history of hypotension, and those with underlying conditions that may be worsened by hypotension and bradycardia; e.g., heart block, bradycardia, cardiovascular disease, vascular disease, cerebrovascular disease, or chronic renal failure. In patients who have a history of syncope or may have a condition that predisposes them to syncope, such as hypotension, orthostatic hypotension, bradycardia, or dehydration, advise patients to avoid becoming dehydrated or overheated.
Source: FDA prescribing information (DailyMed). Set ID: fae2df3c-2298-a3e1-e053-6294a90aeac4. SPL document ID: 2c4def88-252f-7c8b-e063-6294a90aeb94. Label effective date: January 22, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.